Enabling A Four-Fold Increase In Titer For mAb Manufacturing

Achieving higher yields in monoclonal antibody manufacturing is a persistent challenge, particularly under tight development timelines and strict quality requirements. A structured, platform-driven approach to upstream process development can significantly improve productivity by integrating clone selection, experimental optimization, and scalable process design. This strategy begins with identifying high-performing clones through systematic screening and evaluation of productivity and quality attributes. A design-of-experiments methodology is then applied to optimize key variables such as media composition, feeding strategies, seeding density, and process conditions, enabling efficient identification of high-yield configurations. Once optimal conditions are established, the process is scaled up and refined to ensure consistency and robustness in larger bioreactor systems. This integrated approach reduces development time while achieving substantial improvements in output. By enhancing titer and maintaining product quality, such methodologies provide a reliable pathway for efficient, cost-effective biologics production at commercial scale.